Loading chart...



The current price of SPRC is 4.98 USD — it has increased 5.73
Scisparc Ltd, formerly Therapix Biosciences Ltd, is an Israel-based pharmaceutical company committed to creating and enhancing technologies and assets based on cannabinoid pharmaceuticals. The Company is engaged in drug development programs based on repurposing cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), obstructive sleep apnea (OSA) and pain; THX-130 for the treatment of mild cognitive impairment (MCI) and traumatic brain injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.
Wall Street analysts forecast SPRC stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for SPRC is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Scisparc Ltd revenue for the last quarter amounts to 73.71 USD, decreased
Scisparc Ltd. EPS for the last quarter amounts to USD, decreased
Scisparc Ltd (SPRC) has 3 emplpoyees as of July 08 2026.
Today SPRC has the market capitalization of 2.85M USD.